NeuroStrip secures MHRA registration
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Control Bionics Ltd. has announced that its wearable device, NeuroStrip, has received registration from the UK Medicines and Healthcare products Regulatory Agency, allowing for commercial supply in Great Britain. This registration confirms the company's status as a registered medical device manufacturer and enables it to pursue revenue generation across England, Scotland, and Wales. The company is already conducting pilot programs and plans to expand its market entry strategy based on feedback from initial customers. CEO Jeremy Steele emphasized that this milestone supports their global commercial expansion efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Control Bionics
- US FDA Registration and Device Listing for NeuroStrip
- Commercial momentum builds across both platform pillars
- Completion of Placement
- Pause in Trading
- Commercial Momentum Presentation
Later from Control Bionics
- Medicare Billing Code Secured for NextLevel Speech Devices
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Control Bionics into a list and get an email when it puts out news.
Follow Control Bionics